Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
暂无分享,去创建一个
B. Conway | M. Hellard | G. Dore | J. Amin | M. Weltman | G. Foster | A. Dunlop | J. Bruneau | J. Grebely | S. Bourgeois | P. Bruggmann | B. Hajarizadeh | P. Marks | E. Cunningham | O. Dalgard | Sophie Quiene | M. C. Thurnheer | G. Robaeys | H. Midgard | M. Backmund
[1] B. Conway,et al. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. , 2017, The International journal on drug policy.
[2] J. Macías,et al. HCV epidemiology in high-risk groups and the risk of reinfection. , 2016, Journal of hepatology.
[3] D. Nickle,et al. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. , 2016, Annals of internal medicine.
[4] M. Alavi,et al. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. , 2016, Addiction.
[5] D. De Angelis,et al. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence , 2015, Current opinion in infectious diseases.
[6] M. Alavi,et al. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. , 2015, The International journal on drug policy.
[7] M. Hellard,et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] Aasld Idsa Hcv Guidance Panel. Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.
[9] M. Alavi,et al. Continued low uptake of treatment for hepatitis C virus infection in a large community‐based cohort of inner city residents , 2014, Liver international : official journal of the International Association for the Study of the Liver.
[10] M. Abrahamowicz,et al. Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] H. Wand,et al. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011 , 2014, Journal of viral hepatitis.
[12] A. Pharris,et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. , 2014, The International journal on drug policy.
[13] G. Dore,et al. Epidemiology and natural history of HCV infection , 2013, Nature Reviews Gastroenterology &Hepatology.
[14] M. Schaefer,et al. Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] M. Hellard,et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] P. Vickerman,et al. Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] H. Innes,et al. Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. , 2013, The International journal on drug policy.
[18] K. Kielland,et al. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. , 2013, Journal of hepatology.
[19] P. Bruggmann. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers , 2012, Journal of viral hepatitis.
[20] D. D. Des Jarlais,et al. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. , 2012, Addiction.
[21] C. Mcgowan,et al. Barriers to hepatitis C treatment , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[22] G. Dore,et al. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. , 2011, Addiction.
[23] Jing Zhao,et al. Physicians’ attitudes and practice toward treating injection drug users infected with hepatitis C virus: Results from a national specialist survey in Canada , 2011 .
[24] J. Raffa,et al. Impact of hepatitis C virus infection on all‐cause and liver‐related mortality in a large community‐based cohort of inner city residents , 2011, Journal of viral hepatitis.
[25] Judy Gold,et al. Hepatitis C treatment for injection drug users: a review of the available evidence. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] Kenneth A. Harris,et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. , 2009, Journal of substance abuse treatment.
[27] J. Raffa,et al. Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residents , 2009, Journal of viral hepatitis.
[28] Laurent Castera,et al. Non-invasive evaluation of liver fibrosis using transient elastography. , 2008, Journal of hepatology.
[29] S. Mauss,et al. A prospective controlled study of interferon‐based therapy of chronic hepatitis C in patients on methadone maintenance , 2004, Hepatology.
[30] S. Creech,et al. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse , 2003, American Journal of Gastroenterology.
[31] J. Kalbfleisch,et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.
[32] D. Kivlahan,et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. , 1998, Archives of internal medicine.
[33] J. Hoofnagle,et al. Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.